Brian Druker: My Vision for CML and the Road to a Cure
Dr. Brian Druker, a CML expert from OHSU's Knight Cancer Institute and a key researcher responsible for the development of imatinib, gives his perspective about the progress that's been made in research and treatment. He is encouraged that, in most cases, patients can have their disease well managed on existing therapies, while newer agents--some still in trials--will provide even more options for those who are resistant or are experiencing side effects. Dr. Druker explains that he believes CML research can, and should, begin focusing on eradicating the disease altogther, and provides his suggestion about how he believes that might happen.
Experts & Guests
Brian Druker, M.D.
Director, Knight Cancer Institute, OHSU Knight Cancer InstituteDr. Druker specializes in caring for and treating patients with chronic myelogenous leukemia (CML). In his early medical training, witnessing chemotherapy's effects on patients drove him to find a better way to treat cancer. Starting in the lab, he led the development and clinical trials of the drug Gleevec for CML. Gleevec was the first of its kind – a... more >